Sanofi is undergoing a significant leadership transition with Belén Garijo set to replace Paul Hudson as CEO, a change that will officially take effect after the general meeting on April 29, 2026.
This executive shift follows a period of significant stock market underperformance for the pharmaceutical company over the past year. The news has had an immediate impact on Sanofi's stock, which dropped nearly 5% in today's session, falling to 78.67 euros.
This price point is notably below both its 50-day and 200-day moving averages, signaling a weakening medium-term bullish momentum and confirming a southward-oriented fundamental trend. Over the last three months, the stock has seen an 11.66% decline.
In addition to the governance change, Sanofi recently completed the acquisition of Dynavax Technologies, expanding its vaccine portfolio. The company is also preparing for its first-quarter 2026 results publication on April 23, which will be the initial financial assessment under the new leadership.
Sanofi Shares Fall After CEO Change(current)
Data sourced from public RSS feeds and News APIs.
